CITIUS ANNOUNCES CHANGE TO PRIMARY ENDPOINT IN MINO-LOK PHASE 3 STUDY NEW ENDPOINT IMPROVES ABILITY TO CONDUCT STUDY MORE EXPEDITIOUSLY WITH SIGNIFICANTLY FEWER PATIENTS Clinical Trial Cost Savings Estimated to Approach

CITIUS ANNOUNCES CHANGE TO PRIMARY ENDPOINT

IN MINO-LOK PHASE 3 STUDY

NEW ENDPOINT IMPROVES ABILITY TO CONDUCT

STUDY MORE EXPEDITIOUSLY WITH SIGNIFICANTLY FEWER PATIENTS

Clinical Trial Cost Savings Estimated

to Approach $10 million

CRANFORD, N.J. - September 4, 2019 -- Citius Pharmaceuticals,

Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer

care and critical care drug products, today reported that the FDA responded to the Company's proposal to refine the endpoints

in the current Phase 3 pivotal trial for Mino-Lok.

The current Phase 3 trial being conducted compares Mino-Lok therapy

(MLT) to antibiotic lock therapy (ALT) to not only disinfect colonized catheters causing bacteremias, but also to keep the treated

catheters functioning and infection free for 8 weeks post therapy.

The new proposed primary endpoint is planned to demonstrate a significant

difference in the time to catheter failure when comparing MLT to ALT. This is clinically important because eliminating the source

of infection enables antibiotic treatment of the bacteremia to work more effectively and expeditiously. Additionally, if a catheter

can be maintained for the time that it is needed, the patient does not need to be subjected to the procedures for removing and

replacing the catheter that are associated with some serious adverse events.

The FDA noted that time to catheter failure is an acceptable

primary efficacy endpoint. They also instructed the Company to identify and consider the various types of reasons for catheter

failure, and to show the clinical significance of this endpoint.

"Citius is very pleased about the change in efficacy endpoints,"

said Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals. "We believe this focus will allow us to demonstrate

the real benefit of Mino-Lok therapy (MLT) which is that MLT works more efficiently and expeditiously to break up biofilm and eliminate

the bacteria causing the bacteremia than current antibiotic lock therapies (ALTs). We now have a clearer way forward to prove the

superior efficacy of Mino-Lok to ALTs, and we believe we can do this faster with fewer patients than originally planned. At this

time Citius believes that the change to the primary endpoint will result in fewer than 150 total subjects in Phase 3 trial. These

changes would enable Citius to realize clinical trial cost savings approaching $10 million."

The Company has recently submitted a response to the FDA with the

new sample size estimate which the agency is reviewing.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development

and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products

that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to

achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved

drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development

and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to

existing therapeutic approaches. For more information, please visit www.citiuspharma.com.

an antibiotic lock solution used to treat patients with catheter-related blood stream infections (CRBSIs). CRBSIs are

very serious life-threatening infections, especially in cancer patients receiving therapy through central venous catheters (CVCs),

and in hemodialysis patients where venous access presents a challenge. The current Phase 3 trial is being conducted in 36 sites.

There are currently no approved therapies to salvage infected central venous catheters (CVCs).

This press release may contain "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements

are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by

the fact that they use words such as "will," "anticipate," "estimate," "expect," "should,"

and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on

management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating

results, financial condition and stock price.

Factors that could cause actual results to differ materially from

those currently anticipated are: risks associated with the design of our ongoing Phase 3 trial for Mino-Lok, including the change

to the primary endpoint for that trial and our ability to show clinical significance of that endpoint; risks associated with conducting

our Phase 3 trial for Mino-Lok, including completing patient enrollment, patient retention and the reasons for catheter failure

in the trial; risks associated with sourcing components of our product candidates; our dependence on third-party suppliers; our

ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our

product candidates and the acceptance thereof by any market; risks relating to the results of research and development activities;

risks associated with developing Mino-Wrap, including that preclinical results may not be predictive of clinical results and our

ability to file an IND; uncertainties relating to preclinical and clinical testing; the early stage of products under development;

risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully

and on a timely basis; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds;

government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements

contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such

statement is based, except as required by law.

Vice President, Corporate Development